Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies

Journal of the Peripheral Nervous System

Volumn 18, Issue 4, 2013, Pages 275-296

  Berger, Melvin ^a,b   McCallus, Daniel E ^c   Lin, Cindy Shin Yi ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CSL Behring LLC   (United States)

^c Complete Publications Solutions LLC   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

anti idiotypes; autoimmune neuromuscular diseases; chronic inflammatory demyelinating polyneuropathy; Guillain Barr syndrome; intravenous immunoglobulin; multifocal motor neuropathy

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PLACEBO; AUTOANTIBODY; IMMUNOLOGIC FACTOR; PROTEIN BINDING;

ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BINDING COMPETITION; CAMPYLOBACTER JEJUNI; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DEMYELINATION; DRUG MECHANISM; DRUG MEGADOSE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; IN VIVO STUDY; MOTOR NEUROPATHY; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW; ANIMAL; AUTOIMMUNE DISEASES; COMPLICATION; DRUG EFFECTS; METABOLISM; NEUROMUSCULAR DISEASES;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; NEUROMUSCULAR DISEASES; PROTEIN BINDING;

EID: 84890484578     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12048     Document Type: Review

References (194)

1. Anthony RM, Wermeling F, Ravetch JV, (2012). Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 1253: 170-180.
2. Arcila-Londono X, Lewis RA, (2012). Guillain-Barre syndrome. Semin Neurol 32: 179-186.
3. Ariga T, Yu RK, (2005). Antiglycolipid antibodies in Guillain-Barre syndrome and related diseases: review of clinical features and antibody specificities. J Neurosci Res 80: 1-17. (Pubitemid 40577288)
4. Arsura EL, Bick A, Brunner NG, Namba T, Grob D, (1986). High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 146: 1365-1368. (Pubitemid 16075754)
5. Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G, (1994). Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44: 429-432.
6. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B, (1996). Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678-683.
7. Ballow M, (2011). The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127: 315-323.
8. Basta M, Dalakas MC, (1994). High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94: 1729-1735. (Pubitemid 24348207)
9. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD, (2003). F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9: 431-438. (Pubitemid 36460077)
10. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV, (2003a). Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765. (Pubitemid 36077604)
11. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV, (2003b). Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48: 3497-3502. (Pubitemid 37531915)
12. Berger M, Rosenkranz P, Brown CY, (1985). Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 34: 227-236. (Pubitemid 15163040)
13. Bick S, Tschernatsch M, Karg A, Fuehlhuber V, Trenczek TE, Faltermeier K, Hackstein H, Kaps M, Blaes F, (2013). Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy-a new mechanism of action? J Neuroimmunol 256: 84-90.
14. Bird SJ, (2013). Treatment of Myasthenia gravis. Wolters Kluwer Health. Available at: http://www.uptodate.com/contents/treatment-of-myasthenia-gravis. Accessed May 13, 2013.
15. Boerio D, Creange A, Hogrel JY, Gueguen A, Bertrand D, Lefaucheur JP, (2010). Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy. J Neurol Sci 292: 63-71.
16. Bohn AB, Nederby L, Harbo T, Skovbo A, Vorup-Jensen T, Krog J, Jakobsen J, Hokland ME, (2011). The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 18: 919-924.
17. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW, (2008). Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 122: 210-212. (Pubitemid 351899076)
18. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C, (1978). Treatment of acute polyneuropathy by plasma exchange. Lancet 2: 1100. (Pubitemid 9052892)
19. Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Katzberg H, Latov N, Merkies IS, Van Doorn PA, ICE Study Group (2010). Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 42: 492-497.
20. Brown EJ, Berger M, Joiner KA, Frank MM, (1983). Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun 42: 594-598. (Pubitemid 14230251)
21. Broyles R, Rodden L, Riley P, Berger M, (2013). Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders. Postgrad Med 125: 65-72.
22. Buchwald B, Ahangari R, Weishaupt A, Toyka KV, (2005). Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve 31: 487-494. (Pubitemid 40393094)
23. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A, (2003). Acute motor conduction block neuropathy Another Guillain-Barre syndrome variant. Neurology 61: 617-622. (Pubitemid 37082597)
24. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D, (2000). Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 48: 826-832.
25. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, Nobile-Orazio E, (1998). Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 50: 1480-1482. (Pubitemid 28240378)
26. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, van Asseldonk JT, van den Berg LH, van der Pol WL, (2010a). Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 75: 1961-1967.
27. Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, Kuks JB, van Doorn PA, van Engelen BG, Verschuuren JJ, Wokke JH, Veldink JH, van den Berg LH, (2010b). Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75: 818-825.
28. Cavill D, Waterman SA, Gordon TP, (2003). Anti-idiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 48: 3597-3602. (Pubitemid 37531927)
29. Caudie C, Quittard Pinon A, Taravel D, Sivadon-Tardy V, Orlikowski D, Rozenberg F, Sharshar T, Raphael JC, Gaillard JL, (2011). Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barre syndrome patients. J Neurol 258: 1958-1964.
30. Chavada G, Willison HJ, (2012). Autoantibodies in immune-mediated neuropathies. Curr Opin Neurol 25: 550-555.
31. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I, (1993). Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 43: 1911-1917. (Pubitemid 23318855)
32. Choudhary PP, Hughes RA, (1995). Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 88: 493-502.
33. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A, (2011). Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76: 294-300.
34. Cosi V, Lombardi M, Piccolo G, Erbetta A, (1991). Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 84: 81-84.
35. Dacci P, Riva N, Scarlato M, Andresen I, Schmidt D, Comi G, Fazio R, (2010). Subcutaneous immunoglobulin therapy for the treatment of multifocal motorneuropathy: a case report. Neurol Sci 31: 829-831.
36. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B, (2001). High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345: 1870-1876. (Pubitemid 33716561)
37. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE, (1977). Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 297: 1134-1140. (Pubitemid 8272233)
38. Devaux JJ, (2012). Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol 181: 1402-1413.
39. Devaux JJ, Odaka M, Yuki N, (2012). Nodal proteins are target antigens in Guillain-Barre syndrome. J Peripher Nerv Syst 17: 62-71.
40. Dietrich G, Kazatchkine MD, (1990). Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 85: 620-625. (Pubitemid 20087460)
41. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J, (1994). Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 57: 778-783. (Pubitemid 24214955)
42. Drachman DB, Adams RN, Josifek LF, Self SG, (1982). Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307: 769-775. (Pubitemid 12061550)
43. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C, (1986). Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461-465. (Pubitemid 16161945)
44. Edan G, Landgraf F, (1994). Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 57 (Suppl): 55-56. (Pubitemid 24356109)
45. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN, (2009). Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 14: 93-100.
46. Evans MJ, Suenaga R, Abdou NI, (1991). Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunol 11: 291-295.
47. Fahey JL, Sell S, (1965). The immunoglobulins of mice. V. The metabolic (catabolic) properties of five immunoglobulin classes. J Exp Med 122: 41-58.
48. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE, (2000). Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256-1262.
49. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1987). Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol 22: 753-761.
50. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1997). Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 41: 298-306.
51. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A, (1983). Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 80: 7636-7640. (Pubitemid 14177619)
52. Gelfand EW, (2012). Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367: 2015-2025.
53. Goodfellow JA, Bowes T, Sheikh K, Odaka M, Halstead SK, Humphreys PD, Wagner ER, Yuki N, Furukawa K, Plomp JJ, Willison HJ, (2005). Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 25: 1620-1628. (Pubitemid 40279266)
54. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R, (2001). Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 21: 193-199. (Pubitemid 32434306)
55. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE, (1996a). Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119: 1055-1066. (Pubitemid 26300708)
56. Hahn AF, Bolton CF, Zochodne D, Feasby TE, (1996b). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119: 1067-1077. (Pubitemid 26300709)
57. Hansen RJ, Balthasar JP, (2003). Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 92:1206-1215. (Pubitemid 36676467)
58. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J, (2009a). Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16: 631-638.
59. Harbo T, Andersen H, Jakobsen J, (2009b). Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 39: 439-447.
60. Herrmann C Jr, Lindstrom JM, Keesey JC, Mulder DG, (1985). Myasthenia gravis-current concepts. West J Med 142: 797-809. (Pubitemid 15013701)
61. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM, (1995). Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118: 597-605.
62. Holers VM, (2008). The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223: 300-316. (Pubitemid 351986186)
63. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN, (2006). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13: 326-332.
64. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA, (2007). Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130: 2245-2257. (Pubitemid 47327619)
65. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
66. Hughes RA, Swan AV, van Doorn PA, (2012). Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 7: CD002063.
67. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM, (1988). Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 23: 440-447.
68. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP, (1981). High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228-1231.
69. Bonilla FA, (2008). Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 28: 803-819.
70. Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N, (2011). Ataxic Guillain-Barre syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 82: 294-299.
71. Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A, (2012). Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69: 994-1001.
72. Jacobs BC, Bullens RW, O'Hanlon GM, Ang CW, Willison HJ, Plomp JJ, (2002). Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barre syndrome. Muscle Nerve 25: 549-558. (Pubitemid 34293130)
73. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ, (2003). Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220-2234. (Pubitemid 37432366)
74. Jahn K, Franke C, Bufler J, (2000). Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 54: 474-479. (Pubitemid 30078087)
75. Joint Task Force of the EFNS and the PNS (2005). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 10: 220-228.
76. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15: 1-9.
77. Junghans RP, Anderson CL, (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 93: 5512-5516.
78. Kaldor J, Speed BR, (1984). Guillain-Barre syndrome and Campylobacter jejuni: a serological study. Br Med J (Clin Res Ed) 288: 1867-1870. (Pubitemid 14081739)
79. Karnovsky MJ, Unanue ER, (1978). Cell surface changes in capping studied by correlated fluorescence and scanning electron microscopy. Lab Invest 39: 554-564. (Pubitemid 9080662)
80. Kaveri SV, Lacroix-Desmazes S, Bayry J, (2008). The antiinflammatory IgG. N Engl J Med 359: 307-309.
81. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, Toubi E, (2007). Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179: 5571-5575.
82. Kiefer R, Kieseier BC, Stoll G, Hartung HP, (2001). The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109-127. (Pubitemid 32195409)
83. Kiernan MC, Burke D, Andersen KV, Bostock H, (2000). Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23: 399-409. (Pubitemid 30126986)
84. Kim JY, Park KD, Richman DP, (2011). Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol 7: 173-183.
85. Klein CM, Vernino S, Lennon VA, Sandroni P, Fealey RD, Benrud-Larson L, Sletten D, Low PA, (2003). The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53: 752-758. (Pubitemid 36622512)
86. Koga M, Gilbert M, Li J, Koike S, Takahashi M, Furukawa K, Hirata K, Yuki N, (2005). Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 64: 1605-1611. (Pubitemid 40617699)
87. Kokubun N, Sada T, Yuki N, Okabe M, Hirata K, (2013). Optimization of intravenous immunoglobulibn in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. Eur Neurol 70: 65-69.
88. Koski CL, Gratz E, Sutherland J, Mayer RF, (1986). Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome. Ann Neurol 19: 573-577. (Pubitemid 16085191)
89. Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA, (1987). Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin Invest 80: 1492-1497. (Pubitemid 18027796)
90. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC, (2009). Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 66: 597-603.
91. Kuitwaard K, van Doorn PA, Vermeulen M, (2013). Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 84: 859-861.
92. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M, (1998). IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol 44: 202-208. (Pubitemid 28374108)
93. Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD, (1996). Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 14 (Suppl 15): S9-S15. (Pubitemid 26270572)
94. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA, (2010). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 67: 802-807.
95. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N, (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145-153. (Pubitemid 32055996)
96. Lehmann HC, Hartung HP, (2011). Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 231: 61-69.
97. Lehmann HC, Hoffmann FR, Fusshoeller A, Meyer zu Hörste G, Hetzel R, Hartung HP, Schroeter M, Kieseier BC, (2008). The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 271: 34-39.
98. Leontyev D, Katsman Y, Branch DR, (2012a). Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fc g receptor for the amelioration of experimental ITP. Blood 119: 5261-5264.
99. Leontyev D, Katsman Y, Ma XZ, Miescher S, Kasermann F, Branch DR, (2012b). Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion (Paris) 52: 1799-1805.
100. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z, (2005). Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. Clin Invest 115: 3440-3450. (Pubitemid 43121832)
101. Li J, Tüzün E, Wu XR, Qi HB, Allman W, Saini SS, Christadoss P, (2008). Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 194: 44-53.
102. Liblau R, Gajdos P, Bustarret FA, el Habib R, Bach JF, Morel E, (1991). Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 11: 128-131.
103. Lin CS, Krishnan AV, Park SB, Kiernan MC, (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 68: 862-869.
104. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD, (1976). Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
105. Lopez PH, Irazoqui FJ, Nores GA, (2000). Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies. J Neuroimmunol 105: 179-183. (Pubitemid 30160755)
106. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H, (2010). Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125: 1354-1360.
107. Lundkvist I, van Doorn PA, Vermeulen M, Brand A, (1993). Spontaneous recovery from the Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 67: 192-198. (Pubitemid 23186399)
108. Malik U, Oleksowicz L, Latov N, Cardo LJ, (1996). Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 39: 136-139. (Pubitemid 26052229)
109. Mata S, Borsini W, Caldini A, De Scisciolo G, Piacentini S, Taiuti R, (2006). Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy. J Neuroimmunol 181: 141-144. (Pubitemid 44827295)
110. McGonigal R, Rowan EG, Greenshields KN, Halstead SK, Humphreys PD, Rother RP, Furukawa K, Willison HJ, (2010). Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133: 1944-1960.
111. McKhann GM, Griffin JW, Cornblath DR, Quaskey SA, Mellits ED, (1988). Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol. 20: 297-300. (Pubitemid 19008432)
112. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ, Working Group on Peripheral N (2001). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445-449. (Pubitemid 32172866)
113. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M, (2011). A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 16: 92-97.
114. Moskovich O, Fishelson Z, (2007). Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem 282: 29977-29986. (Pubitemid 350035280)
115. Muley SA, Parry GJ, (2012). Multifocal motor neuropathy. J Clin Neurosci 19: 1201-1209.
116. Naba I, Yoshikawa H, Sakoda S, Itabe H, Suzuki H, Kodama T, Yanagihara T, (2000). Onion-bulb formation after a single compression injury in the macrophage scavenger receptor knockout mice. Exp Neurol 166: 83-89.
117. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N, (2007). Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. Arch Neurol 64: 1519-1523. (Pubitemid 47572676)
118. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG, (1978). Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28: 266-272. (Pubitemid 8312875)
119. Nimmerjahn F, Lunemann JD, (2011). Expression and function of the inhibitory Fcgamma-receptor in CIDP. J Peripher Nerv Syst 16 (Suppl 1): 41-44.
120. Nobile-Orazio E, Gallia F, (2013). Multifocal motor neuropathy: current therapies and novel strategies. Drugs 73: 397-406.
121. Nobile-Orazio E, Terenghi F, (2005). IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J Neurol 252 (Suppl 1): I7-I13.
122. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M, Group IMCT (2012). Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11: 493-502.
123. Nunez Miguel R, Sanders J, Chirgadze DY, Furmaniak J, Rees Smith B, (2009). Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol 42: 381-395.
124. Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS, (2008). The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 105: 5471-5476. (Pubitemid 351753887)
125. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT, (2012). Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78: 1009-1015.
126. Peltier AC, Donofrio PD, (2012). Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol 32: 187-195.
127. Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL, (2010). IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 229: 256-262.
128. Pirofsky B, (1984). Intravenous immune globulin therapy in hypogammaglobulinemia. A review. Am J Med. 76: 53-60. (Pubitemid 14126151)
129. Plomp JJ, Willison HJ, (2009). Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol 587: 3979-3999.
130. Pollard JD, Armati PJ, (2011). CIDP-the relevance of recent advances in Schwann cell/axonal neurobiology. J Peripher Nerv Syst 16: 15-23.
131. Press R, Mata S, Lolli F, Zhu J, Andersson T, Link H, (2001). Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barre syndrome. J Neurol Sci 190: 41-47. (Pubitemid 33713020)
132. Press R, Nennesmo I, Kouwenhoven M, Huang YM, Link H, Pashenkov M, (2005). Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 159: 165-176. (Pubitemid 40126189)
133. Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile-Orazio E, Scarlato G, Barbieri S, (2002). Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain 125: 2481-2490.
134. Quick A, Tandan R, (2011). Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 13: 192-198.
135. Rajabally YA, Jacob S, Abbott RJ, (2006). Clinical heterogeneity in mild chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 13: 958-962. (Pubitemid 44284902)
136. Rajabally YA, Wong SL, Kearney DA, (2013). Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol 260: 2052-2056.
137. Rees JH, Gregson NA, Hughes RA, (1995a). Anti-ganglioside GM1 antibodies in Guillain-Barre syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 38: 809-816.
138. Rees JH, Soudain SE, Gregson NA, Hughes RA, (1995b). Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 333: 1374-1379.
139. Reinhart WH, Berchtold PE, (1992). Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339: 662-664.
140. Rhodes KM, Tattersfield AE, (1982). Guillain-Barre syndrome associated with Campylobacter infection. Br Med J (Clin Res Ed) 285: 173-174. (Pubitemid 12079072)
141. Rodriguez O, Collier E, Arakaki R, Gorden P, (1992). Characterization of purified autoantibodies to the insulin receptor from six patients with type B insulin resistance. Metabolism 41: 325-331.
142. Rossi F, Sultan Y, Kazatchkine MD, (1988). Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 74: 311-316.
143. Ruegg SJ, Fuhr P, Steck AJ, (2004). Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63: 2178-2179. (Pubitemid 39636279)
144. Saida K, Sumner AJ, Saida T, Brown MJ, Silberberg DH, (1980). Antiserum-mediated demyelination: relationship between remyelination and functional recovery. Ann Neurol 8: 12-24. (Pubitemid 10056345)
145. Saida K, Saida T, Kayama H, Nishitani H, (1984). Rapid alterations of the axon membrane in antibody-mediated demyelination. Ann Neurol 15: 581-589. (Pubitemid 14124612)
146. Schroeder HW Jr, Cavacini L, (2010). Structure and function of immunoglobulins. J Allergy Clin Immunol 125: S41-S52.
147. Schwab I, Nimmerjahn F, (2013). Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13: 176-189.
148. Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, Kanai K, Noto Y, Fujimaki Y, Shibuya K, Ohmori S, Sato Y, Kuwabara S, (2012). Antiganglioside antibodies are associated with axonal Guillain-Barre syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 83: 23-28.
149. Serra A, Ruff RL, Leigh RJ, (2012). Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles. Ann N Y Acad Sci 1275: 129-135.
150. Shahrizaila N, Yuki N, (2013). Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 84: 576-583.
151. Shiraishi H, Motomura M, Iwanaga H, Tsujino A, Nishiura Y, Shirabe S, Nakamura T, Yoshimura T, (2002). Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy. Rinsho Shinkeigaku 42: 766-770. (Pubitemid 36362458)
152. Smith AJ, Jackson MW, Wang F, Cavill D, Rischmueller M, Gordon TP, (2005). Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjögren syndrome. Hum Immunol 66: 411-416. (Pubitemid 40615797)
153. Spiegel S, Kassis S, Wilchek M, Fishman PH, (1984). Direct visualization of redistribution and capping of fluorescent gangliosides on lymphocytes. J Cell Biol 99: 1575-1581. (Pubitemid 15223592)
154. Sung JY, Kuwabara S, Kaji R, Ogawara K, Mori M, Kanai K, Nodera H, Hattori T, Bostock H, (2004). Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: correlation with clinical profiles. Muscle Nerve 29: 28-37. (Pubitemid 38040553)
155. Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, Rasband MN, (2012). Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233: 534-542.
156. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lunemann JD, (2009). Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 106: 4788-4792.
157. Tandon N, Jayne DR, McGregor AM, Weetman AP, (1992). Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. J Autoimmun 5: 557-570.
158. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E, (2004). How long is IVIg effective in multifocal motor neuropathy? Neurology 62: 666-668. (Pubitemid 38252820)
159. Tharakan J, Ferner RE, Hughes RA, Winer J, Barnett M, Brown ER, Smith G, (1989). Plasma exchange for Guillain-Barre syndrome. J R Soc Med 82: 458-461. (Pubitemid 19191220)
160. Titulaer MJ, Lang B, Verschuuren JJ, (2011). Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10: 1098-1107.
161. Tonegawa S, (1983). Somatic generation of antibody diversity. Nature 302: 575-581.
162. Ueda A, Shima S, Miyashita T, Ito S, Ueda M, Kusunoki S, Asakura K, Mutoh T, (2010). Anti-GM1 antibodies affect the integrity of lipid rafts. Mol Cell Neurosci 45: 355-362.
163. Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, Matre R, (1994). Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol 56: 732-740.
164. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FG, Wokke JH, (1995). Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248-252.
165. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN, (2010). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 17: 356-363.
166. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH, (2002). Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125: 1875-1886.
167. Van der Meche FG, Schmitz PI, (1992). A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326: 1123-1129.
168. Van Doorn PA, Brand A, Vermeulen M, (1987). Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 37: 1798-1802. (Pubitemid 17163726)
169. Van Doorn PA, Brand A, Vermeulen M, (1988). Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin. Neurology 38: 1592-1595.
170. Van Doorn PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD, (1990). On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 29: 57-64. (Pubitemid 20283782)
171. Van Doorn PA, Kuitwaard K, Jacobs BC, (2011). Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst 16 (Suppl 1): 38-40.
172. Van Sorge NM, Van den Berg LH, Geleijns K, Van Strijp JA, Jacobs BC, Van Doorn PA, Wokke JH, Van de Winkel JG, Leusen JH, Van der Pol WL, (2003). Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol 53: 570-579. (Pubitemid 36529430)
173. Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS, (2013). Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG-the ICE study. Eur J Neurol 20: 748-755.
174. Vincent A, Whiting PJ, Heidenreich F, Roberts A, (1988). Monoclonal anti-acetylcholine receptor antibodies as probes for human acetylcholine- receptor in myasthenia gravis. J Recept Res 8: 143-159.
175. Vincent A, Lang B, Kleopa KA, (2006). Autoimmune channelopathies and related neurological disorders. Neuron 52: 123-138. (Pubitemid 44466364)
176. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH, (2012). Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8: 48-58.
177. Vriesendorp FJ, (2013). Pathogenesis of Guillain-Barre syndrome in adults. Available at: http://www.uptodate.com/contents/pathogenesis-of-guillain- barre-syndrome-in-adults. Accessed May 13, 2013.
178. Vriesendorp FJ, Mayer RF, Koski CL, (1991). Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barre syndrome treated and not treated with plasmapheresis. Arch Neurol 48: 858-861.
179. Vucic S, Kiernan MC, Cornblath DR, (2009). Guillain-Barre syndrome: an update. J Clin Neurosci 16: 733-741.
180. Waldmann TA, Strober W, (1969). Metabolism of immunoglobulins. Prog Allergy 13: 1-110.
181. Walport MJ, (2001). Complement. First of two parts. N Engl J Med 344: 1058-1066.
182. Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, Waldmann TA, Robinson JM, Anderson CL, (2006). Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci USA 103: 5084-5089.
183. Willison HJ, Yuki N, (2002). Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625. (Pubitemid 35423511)
184. Xia Y, Kellems RE, (2011). Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 7: 659-674.
185. Yu Z, Lennon VA, (1999). Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340: 227-228. (Pubitemid 29063222)
186. Yuki N, (2012). Guillain-Barre syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci 88: 299-326.
187. Yuki N, Hartung HP, (2012). Guillain-Barre syndrome. N Engl J Med 366: 2294-2304.
188. Yuki N, Miyagi F, (1996). Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 139: 160-162. (Pubitemid 26246296)
189. Yuki N, Yoshino H, Sato S, Miyatake T, (1990). Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40: 1900-1902.
190. Yuki N, Tagawa Y, Hirata K, (1998). Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 51: 875-877. (Pubitemid 28449278)
191. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K, (2001). Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49: 712-720. (Pubitemid 32530237)
192. Yuki N, Watanabe H, Nakajima T, Spath PJ, (2011). IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 82: 87-91.
193. Zerbi D, Celano I, Forlani G, Garelli S, Mosconi L, Valbonesi M, (1981). Plasmapheresis in the treatment of four cases of Guillain-Barre syndrome (acute form). Ital J Neurol Sci 2: 331-336. (Pubitemid 12174347)
194. Zhang G, Lopez PH, Li CY, Mehta NR, Griffin JW, Schnaar RL, Sheikh KA, (2004). Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 127: 1085-1100. (Pubitemid 38623044)